| Type 1 Excludes |
| antiphospholipid syndrome (D68.61) |
| lupus anticoagulant (D68.62) |
| secondary activated protein C resistance (D68.69) |
| secondary antiphospholipid antibody syndrome (D68.69) |
| secondary lupus anticoagulant with hypercoagulable state (D68.69) |
| secondary systemic lupus erythematosus [SLE] inhibitor with hypercoagulable state (D68.69) |
| systemic lupus erythematosus [SLE] inhibitor finding without diagnosis (R76.0) |
| systemic lupus erythematosus [SLE] inhibitor with hemorrhagic disorder (D68.312) |
| thrombotic thrombocytopenic purpura (M31.1) |
| Alternate Description |
| Primary hypercoagulable states |
|
D68.51 |
|
Activated protein C resistance |
|
D68.52 |
|
Prothrombin gene mutation |
|
D68.59 |
|
Other primary thrombophilia |
